Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Rectal,Topical,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | India | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Austin Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Varicose Veins|Varicose Ulcer|Esophageal and Gastric Varices
Phase 1: Pilonidal Sinus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400080913 | N/A |
Not yet recruiting |
Coronary Artery Disease |
2026-12-31 |
|
| HISTOLAP | N/A |
Recruiting |
Other |
2024-12-31 |
|
| KUH5200627 | N/A |
Unknown status |
Pain, Postoperative |
2019-03-01 |
|
| Histoacryl1 | N/A |
Completed |
Pain, Postoperative|Acute Pain|Chronic Pain |
2016-12-01 |